Strålende presentasjon fra BGBIO v/ Akil Jackson
Medical Director, BerGenBio ASA

- ACCORD studiene går som planlagt iflg Akil Jackson som nettopp har deltatt i en diskusjon med tema :

«Potential Therapeutic Strategies to Prevent & Conquer Covid-19 Panel »

( Akil Jackson presenterer også BGBIO 9. Juli kl 11:15 )

DIGITAL NOVEL CORONAVIRUS INVESTMENT FORUM : https://ncif.sachsevent.com/event/1/about

7ᵀᴴ - 9ᵀᴴ July 2020
The live programme will begin at 14:00 (CET) on the 8ᵀᴴ of July

The Digital Novel Coronavirus Investment Forum is a forward-looking analysis of the revolution in healthcare caused by the pandemic and the consequent exciting drive for innovation in the Life Sciences, HealthTech and Digital sectors. The virtual NCIF conference is going to take place on the 7ᵀᴴ-9ᵀᴴ of July with main programme being spread throughout 3 days and will include over ten hours of high-level speeches and panel discussions. In addition, there is a global company showcase of around 40 presentations by corporates, offering innovative solutions and looking for capital and partnerships. The virtual event will be held in Central European Time Zone and will start at 13:30PM CET.



Akil Jackson
Medical Director, BerGenBio ASA


Akil Jackson is a Medical Director with BerGenBio since 2018, responsible for clinical development and translational research related to non-oncology aspects of pipeline. After completing medical training and internship at the University of the West Indies (Kingston, Jamaica) and completing his MRCP at the Chelsea & Westminster hospital, London, he joined the the St. Stephens AIDS Trust clinical research unit (under Prof. Brian Gazzard), where over a decade he was clinical investigator on over 180 studies, ranging from phase 1 through to 4. This work predominantly focussed on early phase development of therapies and strategies for the treatment or prevention of HIV. Through this close collaboration with the HIV clinical pharmacology group at the University of Liverpool (Prof. David Back) he was awarded a PhD on novel approaches to dose optimisation and drug formulation, using drug nanoparticles, for the treatment and prevention of HIV. Prior to joining BerGenBio, he worked at Gilead UK in the commercial launch of successive hep C combination therapies, clinically lead the successful reimbursement via health technology assessments for of the first pangenotypic therapies at each devolved nation of the UK. Since Autumn 2019, he has lead the formation of the Caribbean collaboration between the International Collaboration on Nutrition in relation to Cancer (ICONIC), the University of the West Indies and the Caribbean Institute for Health Research (CAIHR). ICONIC is a formal Task Force of the International Union of Nutritional Sciences (IUNS).